Guardant Health (GH) Company Report

Guardant Health reported strong financial performance for 2025, with $281 million in Q4 revenue, representing 39% year-over-year growth, and $982 million for the full year, up 33% year-over-year. The non-GAAP gross margin improved to 66% for both Q4 and the full year 2025.
The Shield screening business demonstrated significant growth, generating $35 million in Q4 2025 revenue from approximately 38,000 tests and $79.7 million for the full year from 87,000 tests. Guardant secured a $1,495 reimbursement rate for Shield through December 2027 and expanded its commercial reach through collaborations with Quest Diagnostics and PathGroup.
For full year 2026, Guardant Health projects total revenue between $1.25 billion and $1.28 billion, indicating 27%-30% growth. Screening revenue is expected to significantly increase to $162 million-$174 million from 210,000-225,000 tests.
The company ended 2025 with approximately $1.3 billion in cash and improved its free cash flow burn to $233 million for the year. The core business (excluding screening) was free cash flow positive in Q3 and Q4 2025 and is expected to be free cash flow positive for the full year 2026, with a commitment to company-wide cash flow breakeven by the end of 2027.
Guardant acquired MetaCyte Diagnostics for $59 million upfront cash to enhance its product portfolio and accelerate its multi-disease detection pipeline. Additionally, Shield was expanded to include multi-cancer detection results, and Reveal received Medicare coverage for CRC surveillance in early 2025.

7 days ago

Transcript

Guardant Health Announces Q4 and Full Year 2025 Results and 2026 Guidance

Earnings

Guidance Update

M&A

Guardant Health reported strong revenue growth in Q4 and full-year 2025, with total revenue reaching $281 million in Q4 2025 (39% year-over-year growth) and $982 million for the full year (33% year-over-year growth). Oncology revenue grew 30% year-over-year in Q4 2025 to $190 million, driven by a 38% increase in oncology volume.
The company achieved a non-GAAP gross margin of 66% for both Q4 and full-year 2025, with Adjusted EBITDA at $(65) million in Q4 2025 and $(221) million for the full year.
Shield volume demonstrated significant sequential growth, reaching 38K tests in Q4 2025 and contributing $35 million in Q4 2025 revenue. The company also announced the acquisition of MetaSight Diagnostics.
For full-year 2026, Guardant Health initiated guidance projecting total revenue between $1.25 billion and $1.28 billion (27%-30% year-over-year growth) and a non-GAAP gross margin of 64%-65%. The company is targeting free cash flow breakeven in Q4 2027.

7 days ago

Presentation

Guardant Health Reports Strong Q4 and Full-Year 2025 Results, Provides Optimistic 2026 Guidance

Earnings

Guidance Update

M&A

Guardant Health reported strong financial performance for Q4 and full-year 2025, with total revenue reaching $982 million for the full year, a 33% year-over-year increase.
The company provided an optimistic outlook for 2026, forecasting total revenue between $1.25 billion and $1.28 billion, representing 27%-30% growth, and expects its core business (excluding screening) to be free cash flow positive for the full year 2026.
The Shield screening business demonstrated significant growth, with $79.7 million in revenue from 87,000 tests in 2025, and is projected to more than double in 2026 to $162 million-$174 million from 210,000-225,000 tests, supported by new collaborations and expanded coverage.
Strategic developments include the launch of Guardant Reveal for therapy monitoring, new Guardant360 CDx approvals, and the acquisition of MetaCyte for $59 million upfront, enhancing the product portfolio and accelerating multi-disease detection.

7 days ago

Transcript

Guardant Health Announces Strong Q4 and Full Year 2025 Results with Positive 2026 Outlook

Earnings

Guidance Update

Revenue Acceleration/Inflection

Guardant Health reported Q4 2025 revenue of $281 million, a 39% year-over-year increase, and full-year 2025 revenue of $982 million, up 33%.
The company's oncology business saw Q4 revenue grow 30% to $190 million with volumes up 38% to approximately 79,000 tests, while the Shield screening business generated $35 million in Q4 revenue from 38,000 tests.
Non-GAAP gross margin improved to 66% for both Q4 and the full year 2025, up from 63% and 62% respectively in the prior year, driven by reduced cost per test for Reveal and Shield.
For full-year 2026, Guardant Health expects total revenue between $1.25 billion and $1.28 billion, representing 27%-30% growth, with screening revenue projected to be $162 million-$174 million.
The company aims for company-wide cash flow breakeven by the end of 2027 and ended 2025 with approximately $1.3 billion in cash after acquiring MetaSyte Diagnostics for $59 million upfront.

7 days ago

Transcript

Guardant Health Reports Q4 and Full Year 2025 Financial Results and Provides 2026 Outlook

Earnings

Guidance Update

Revenue Acceleration/Inflection

Guardant Health reported total revenue of $281.3 million for Q4 2025, a 39% increase from the prior year period, and $982.0 million for the full year 2025, up 33% from 2024.
The company's non-GAAP gross margin improved to 66% for both Q4 2025 and full year 2025, compared to 63% and 62% respectively in 2024.
Full year 2025 free cash flow burn improved to $(233) million, from $(275) million in 2024.
Guardant Health expects full year 2026 total revenue to be in the range of $1.25 billion to $1.28 billion, representing 27% to 30% growth year-over-year.
As of December 31, 2025, the company had $1.3 billion in cash, cash equivalents, restricted cash, and marketable debt securities.

7 days ago

8-K

Guardant Health Reports Strong Q4 and Full Year 2025 Financial Results and Provides 2026 Outlook

Earnings

Guidance Update

Revenue Acceleration/Inflection

Guardant Health reported Q4 2025 revenue of $281.3 million, a 39% increase year-over-year, and full year 2025 revenue of $982.0 million, up 33% from 2024, driven by strong performance across Oncology and Screening.
For the full year 2025, the company achieved a non-GAAP gross margin of 66% and improved its free cash flow burn to $(233) million.
The company expects full year 2026 total revenue to be in the range of $1.25 to $1.28 billion, representing 27% to 30% growth over 2025, with a non-GAAP gross margin of 64% to 65% and free cash flow burn of $185 to $195 million.
In November 2025, Guardant Health completed a public offering, receiving $327.3 million in net proceeds, and issued $402.5 million in convertible senior notes, contributing to $1.3 billion in cash, cash equivalents, restricted cash, and marketable debt securities as of December 31, 2025.

7 days ago

Press Release

Guardant Health Study Shows Guardant Reveal Blood Test Identifies Colon Cancer Recurrence Risk

Product Launch

New Projects/Investments

Guardant Health announced the publication of the largest study to date evaluating circulating tumor DNA (ctDNA) for molecular residual disease (MRD) detection in patients with resected stage III colon cancer.
The study, published in the Journal of Clinical Oncology, found that the Guardant Reveal blood test better predicts recurrence and overall survival than standard staging.
Guardant Reveal identified patients with detectable ctDNA after surgery at a four-to-six-fold higher rate of disease recurrence or reduced survival.
These findings support the integration of tissue-free ctDNA testing into routine postoperative management to better identify high-risk patients who may benefit from intensified surveillance or alternative adjuvant strategies.
Guardant has also expanded Reveal to support late-stage therapy response monitoring across solid tumors.

Feb 2, 2026, 1:05 PM

Press Release

Guardant Health Announces Multi-Year Strategic Collaboration with Merck

New Projects/Investments

Product Launch

Guardant Health has entered into a multi-year strategic collaboration agreement with Merck (known as MSD outside the United States and Canada).
This collaboration aims to support the development and commercialization of Merck’s oncology portfolio using Guardant’s Infinity™ Smart platform.
The agreement includes utilizing Guardant’s liquid and tissue biopsy tests as clinical trial enrolling assays in Merck’s global studies and evaluating their use as companion diagnostics for novel therapies.
The partnership also covers the global commercialization of drugs and companion diagnostics in markets such as the US, Asia-Pacific, UK, and EU.

Jan 19, 2026, 1:05 PM

Press Release

Guardant Health Reports Strong 2025 Financials and Outlines 2026 Growth Drivers

Revenue Acceleration/Inflection

Product Launch

New Projects/Investments

Guardant Health reported $981 million in revenue for 2025, representing 33% year-over-year growth, with Q4 2025 revenue at $280 million, up 39% year-over-year.
Oncology volumes accelerated to 276,000 tests in 2025, a 34% year-over-year increase, while Shield test volumes reached 38,000 in Q4 2025, a significant step up from 24,000 in Q3 2025.
The company ended 2025 with approximately $1.3 billion in cash and anticipates achieving free cash flow breakeven by Q4 2027, pulling forward its long-term profitability guidance by one year.
Key product developments include the Q4 2025 launch of Reveal therapy monitoring , the planned 2026 commercial launch of Reveal Ultra , and the expansion of Shield to include a multi-cancer findings report.
Strategic collaborations with Quest Diagnostics and PathGroup are set to broaden Shield's national reach in 2026, with the Quest Diagnostics collaboration on track to launch in Q1 2026.

Jan 12, 2026, 11:45 PM

Transcript

Guardant Health Reports Strong 2025 Revenue Growth and Targets 2027 Free Cash Flow Breakeven

Earnings

Guidance Update

Revenue Acceleration/Inflection

Guardant Health reported strong revenue growth in 2025, with Q4 2025 revenue of $280 million (39% YoY growth) and full-year 2025 revenue of $981 million (33% YoY growth).
The company is targeting free cash flow breakeven in Q4 2027 and reported $1.3 billion in cash at year-end 2025.
Oncology volume grew by 34% in 2025 to 276K, and Shield CRC screening volumes reached 38K in Q4 2025.
Key catalysts for 2026 include the planned launch of Guardant Reveal Ultra, Guardant360 Liquid FDA approval, and the launch of the Quest Diagnostics collaboration.

Jan 12, 2026, 11:45 PM

Presentation

Earnings Transcripts

Quarterly earnings call transcripts for Guardant Health.

Q4 2025

Feb 19, 2026

→

Q3 2025

Oct 29, 2025

→

Q2 2025

Jul 30, 2025

→

Q1 2025

Apr 30, 2025

→

View All Transcripts

Ask Fintool AI Agent

Get instant answers from SEC filings, earnings calls & more

What did AmirAli Talasaz say about margins?What are Guardant Health's strategic priorities?How is Guardant Health positioned vs competitors?How did Guardant Health do last quarter?

Guardant Health (GH)

Analyst Earnings Quarterly Reports

Q3 2025

Q2 2025

Q1 2025

Q4 2024

Executives

AmirAli Talasaz

Helmy Eltoukhy

Christopher Freeman

Craig Eagle

Darya Chudova

John Saia

Kumud Kalia

Michael Bell

Terilyn Juarez Monroe

Board Members

Alex Azar

Ian Clark

Manuel Hidalgo Medina

Meghan Joyce

Musa Tariq

Myrtle Potter

Roberto Mignone

Steve Krognes

Vijaya Gadde

Analyst Coverage

Mark Massaro

Puneet Souda

Tycho Peterson

Kyle Mikson

Daniel Brennan

Bill Bonello

Luke Sergott

Subbu Nambi

Subhalaxmi Nambi

William Bonello

Andrew Brackmann

Casey Woodring

Daniel Arias

Daniel Markowitz

Dan Leonard

Doug Schenkel

Eve Burstein

Jack Meehan

Patrick Donnelly

Paul

Rachel Vatnsdal Olson

Tejas Savant

Aaron

Aaron Ryskin

Dan Arias

Daniel Leonard

Douglas Schenkel

Mason Carrico

Matthew Sykes

Rachel Vatnsdal

Salem Salem

Yuko Oku

Latest news

Earnings Transcripts

Q4 2025

Q3 2025

Q2 2025

Q1 2025

Ask Fintool AI Agent